CYTK Q2 2021 Earnings — Cytokinetics, Incorporated Revenue & Financial Results | Market Cap Arena

CYTKCytokinetics, Incorporated

$8B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3M-20.9% YoY

Gross Profit

-$34M-1181.9% margin

Operating Income

-$55M-1927.4% margin

Net Income

-$62M-2165.1% margin

EPS (Diluted)

$-0.86

QoQ Revenue Growth

-56.6%

Cash Flow

Operating Cash Flow

-$29M

Free Cash Flow

-$38M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$564M

Total Liabilities

$548M

Stockholders' Equity

$16M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3M	$4M	-20.9%
Gross Profit	-$34M	-$18M	-84.6%
Operating Income	-$55M	-$32M	-69.3%
Net Income	-$62M	-$41M	-50.9%

Revenue Segments

Research And Development

$3M53%

Research And Development Milestone Grant And Other Revenues Net

$3M47%